Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer
|
|
- Hector Griffith
- 6 years ago
- Views:
Transcription
1 REVIEW ARTICLE Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer A Meta-Analysis Xingxing Chen, MD,* Haizhou Zou, MD,Þ Huifang Li, MD,* Ruifang Lin, MD,* Meng Su, MD,* Wenyi Zhang, MD,* Yongqiang Zhou, MD,* Ping Zhang, MD,* Meng Hou, PhD,* Xia Deng, MD,* and Changlin Zou, MD* Background: The aim of this study was to evaluate toxicity, compliance, recurrence and the survival of weekly and triweekly cisplatin-based concomitant chemoradiation in treatment of cervical cancer. Materials and Methods: The databases were searched from 1995 until 2015 to identify eligible studies on weekly versus triweekly cisplatin chemoradiotherapy. The data were analyzed by RevMan 5.3 software. Results: A total of 5 randomized controlled trials were included in this review. Weekly cisplatin regimen significantly reduced the incidence of Hematologic toxicity. However, there was no significantly different between the 2 arms in compliance, recurrence and the survival rate (all P 90.05). Conclusions: Weekly cisplatin regimen had the similar therapeutic effect as the triweekly cisplatin regimen but with less hematologic toxicity. Therefore, we recommend the weekly cisplatin 30 to 40 mg/m 2 chemoradiotherapy as the strong candidate for the optimal cisplatin dose and dosing schedule in the treatment of locally advanced cervical cancer. Key Words: Cervical cancer, Chemoradiotherapy, Cisplatin, Weekly, Triweekly Received July 29, 2016, and in revised form September 14, Accepted for publication October 5, (Int J Gynecol Cancer 2017;27: 344Y349) ervical carcinoma is one of the most common gynecologic malignancies worldwide, and advanced disease carries C a poor prognosis. 1 On the basis of the consistent results of 5 large *Department of Chemoradiation Oncology, The First Affiliated Hospital of Wenzhou Medical University; Department of Oncology, Wenzhou Hospital of Traditional Chinese Medicine, Wenzhou, Zhejiang, P.R. China. Address correspondence and reprint requests to Changlin Zou, MD, Department of Chemoradiation Oncology, the First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Street, Wenzhou, , Zhejiang, P.R. China. zcl @163.com. X.C. and H.Z. contributed equally to this work. The authors declare no conflicts of interest. Copyright * 2016 by IGCS and ESGO ISSN: X DOI: /IGC randomized trials, which demonstrated improvements in survival rate, cisplatin-based concomitant chemoradiation has become the standard treatment for locally advanced cervical cancer. 2Y6 The 2 trials adopted weekly cisplatin 40 mg/m 2 among the previous 5 randomized clinical trials, while the other 3 trials used triweekly cisplatin at a dose range of 50 to 75 mg/m 2 combined with 5-fluorouracil (5-FU). 2Y6 Despite the variety in cisplatin dose and dosing schedules, the optimal chemotherapy regimen is still undetermined. The study performed by the Gynecologic Oncology Group found that intravenous infusion of 5-FU in combination with pelvic radiotherapy was not likely to achieve a better outcome over weekly cisplatin, the role of 5-FU, which previously popularly included in clinical trials, as a radiosensitizer became subject to debate. 7 Weekly cisplatin concurrent with radiation is widely accepted as the standard regimen of chemoradiation by reason 344 International Journal of Gynecological Cancer & Volume 27, Number 2, February 2017
2 International Journal of Gynecological Cancer & Volume 27, Number 2, February 2017 Weekly vs Triweekly Cisplatin Chemoradiotherapy of its convenience, favorable toxicity, and equal effectiveness. A previous study demonstrated that the regimen of chemoradiation using weekly cisplatin significantly improves compliance with treatment and reduces acute hematologic toxicity, whereas not affecting response and survival rates. 8 However, a randomized trial observed a tendency of superiority in triweekly cisplatin 75 mg/m 2 chemotherapy concurrent with radiotherapy as far as overall survival (OS) and disease-free survival were concerned. 9 In addition, Ryu et al 10 reported that triweekly cisplatin regimen was more effective than the conventional weekly cisplatin regimen and may be a strong candidate for the optimal cisplatin dose and dosing schedule in the treatment of locally advanced cervical cancer. In light of the results of the previous clinical trial that indicated 5-FU may not be an active radiosensitizer, weekly cisplatin 40 mg/m 2 and triweekly cisplatin 75 mg/m 2 remain the most popular cisplatin doses and dosing schedules. In order to analyze systematically which regimen is better, a meta-analysis has been conducted to compare differences between weekly and triweekly cisplatin arms. 11 Nevertheless, the studies evaluated in the research are not all randomized controlled trials (RCTs), along with 2 of the articles from different stages of the same study, which impairs validity and credibility of the result. Consequently, the aim of this study was to evaluate adverse effect and survival of 2 regimens more fully and precisely. MATERIALS AND METHODS Search Strategy The electronic databases of PubMed, EMBASE, the Cochrane Library of Controlled Trials, and Web of Science were searched from May 1995 until December 2015 to identify studies on weekly versus triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of cervical cancer. The core search consisted of terms related to cancer sites (cervical OR uterine cervical OR cervix uteri) and descriptions of cancer (cancer OR neoplasm OR carcinoma OR tumor). These were combined with specific terms for treatments (chemoradiotherapy OR chemoradiation OR radiochemotherapy OR chemotherapy OR radiotherapy OR radiation) and cycle of treatments (weekly OR Triweekly). Only studies in English were considered. An additional search was carried out by manually reviewing the references of topical papers and checked for potentially relevant studies. Inclusion and Exclusion Criteria Studies were included in the analysis if: (1) publication in English; (2) RCT design, and conducted on the treatment of cervical cancer with weekly versus triweekly chemotherapy arms concurrent with radiotherapy; (3) no evidence of para-aortic lymph node or distant metastasis on pretreatment imaging (stage I to IVA); and (4) the long-term OS and progression-free survival (PFS) were assessed as outcomes to measure the effect of the treatment. If studies were duplicates, the study with the most up-to-date results was included. Studies were excluded if patients had previous histories of chemotherapy or radiotherapy, histories of rare tumor, such as melanoma and metastatic cancers, serious medical disease or pregnant state. Data Collection and Extraction To identify studies for inclusion in the analysis, we reviewed all resulting article titles and abstracts, and then obtained the full text for the determination of eligibility. Two independent investigators retrieved and evaluated all eligible studies. Any discrepancies were resolved by an independent investigator. Toxicity, compliance, recurrence, the OS and PFS were the outcomes of interest. Data were extracted and entered into the Excel database that included first author, title of trial and country, year of publication and study design, number of participants, and their basic characteristics data. Methodological Quality According to the Cochrane Handbook for Systematic Reviews of Interventions, 12 all RCTs should be assessed on the following domains: random sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting, and other possible bias. This assessment was performed independently by 2 reviewers. If any disagreements arise, a consensus should be reached by discussion. Statistical Analysis The data were analyzed by RevMan 5.3 software in this meta-analysis, and statistical heterogeneity between studies was examined using the W 2 test and the I 2 statistic. P G 0.05 indicating heterogeneity and I 2 values of 25%, 50%, and 75% corresponded to minimal, moderate and substantial degrees of heterogeneity, respectively. 13 When statistically significant heterogeneity was observed, the random-effect model was used for meta-analysis. Alternatively, the fixed-effect model was used. If the grade of heterogeneity was too large, descriptive analysis was used. The toxic effects, rates of compliance and recurrence and the survival rates were estimated using the odds ratios with the corresponding 95% confidence intervals (CI) and P values. P less than 0.05 was considered statistically significant. The Begg funnel plot was used to detect potential publication bias. RESULTS Study Selection The search strategy initially provided 4756 potentially relevant articles. Among these studies, 385 of the studies published in English involved randomized controlled trials. After excluding irrelevant papers by reviewing the titles and abstracts, 11 reports remained. Among them, the following 6 articles were excluded from the final assessment: full text not available (n = 2), duplicate study (n = 2), studies had fewer than 50 samples (n = 1), outcomes did not include complete data (n = 1). Eventually, a total of 5 trials 8Y10,14,15 were included in this review for further analysis. Characteristics of Eligible Studies Five randomized trials in the United States, Korea and Romania were published between 2007 and 2014, with the number of the included patients reaching Of these, * 2016 IGCS and ESGO 345
3 Chen et al International Journal of Gynecological Cancer & Volume 27, Number 2, February 2017 TABLE 1. Characteristics of the included studies Author Year Country Method Stage N (QW/Q3W) Treatment DiSilvestro 2014 USA RCT IB2YIVA 194/185 QW: CIS 40 mg/m 2, 6 cycles Q2W:CIS 75 mg/m 2, 3 cycles Combined TPZ Viorica 2012 Romania RCT IIBYIIIB 162/164 QW: CIS 40 mg/m 2, 6 cycles Q3W:CIS 20 mg/m 2 per day, 5 d, 3 cycles Ryu 2011 Korea RCT IIBYIVA 51/53 QW: CIS 40 mg/m 2, 6 cycles Q3W:CIS 75 mg/m 2, 3 cycles Kim 2007 Korea RCT IIBYIVA 77/78 QW: CIS 30 mg/m 2, 6 cycles Q4W: CIS 20 mg/m 2 /d, 5 d, 3 cycles combined FU 1 mg/m 2 per day, 5 d Rose 2007 USA RCT IIBYIVA 176/173 QW: CIS 40 mg/m 2, 6 cycles Q4W: CIS 50 mg/m 2 per day, 2 cycles combined FU 4 mg/m 2 per 96 h, Hydroyurea 2 mg/m 2, twice per week CIS, cisplatin; QW/Q3W, weekly/triweekly; TPZ, tirapazamine. 660 patients received weekly cisplatin-based chemotherapy arm concurrent with radiotherapy and the remaining 653 patients received triweekly arm. All studies included in our meta-analysis were randomized and controlled. However, none of them was a double-blinded study due to the nature of the trials. Only one study 10 had mentioned that all the investigators were masked to the assignment of treatment group. And information on selective reporting was not mentioned in any of the studies. Thus, the studies have a moderate risk of bias. The characteristics of the trials and the risk of bias summary are presented in Table 1 and Figure 1, respectively. Toxic Effects The main chemotherapy related adverse events were hematologic toxicity, gastrointestinal toxicity and so on. Hematologic toxicity was reported in 3 trials and 2 of them reported the event number of grade 3 and 4 leukopenia and thrombocytopenia. Weekly cisplatin regimen significantly reduced the incidence of hematotoxicity (odds ratio, 0.62; 95% CI, 0.46Y0.83, P = 0.001, Fig. 2) compared with triweekly regimen. Gastrointestinal complications (reported in 3 trials) including grade 3 or 4 nausea, vomiting or diarrhea. There was no different between the 2 arms in the risk of gastrointestinal toxicity (odds ratio, 0.72; 95% CI, 0.37Y1.43, P = 0.35, Fig. 3). Compliance and Recurrence The rate of compliance was extracted from 3 of the 5 included studies. The analysis found that weekly cisplatin FIGURE 1. Risk of bias summary. 346 * 2016 IGCS and ESGO
4 International Journal of Gynecological Cancer & Volume 27, Number 2, February 2017 Weekly vs Triweekly Cisplatin Chemoradiotherapy FIGURE 2. Forest plot of hematologic toxicity. chemotherapy concurrent with radiotherapy was not significantly superior to the triweekly cisplatin arm (odds ratio, 0.62; 95% CI, 0.21Y1.79, P = 0.38). And the rate of recurrence, which was reported in all 5 trials, was similar between the weekly and triweekly chemotherapy regimens (odds ratio, 1.19; 95% CI, , P =0.17). Survival Rates The OS was mentioned in all of the 5 studies. Three trials reported the 5-year OS, Kim2008evaluated the 4-year OS and DiSilvestro 2014 showed the 3-year OS. The analysis for the OS of the 2 cisplatin schedules did not find significantly statistical difference (odds ratio, 0.83; 95% CI, 0.66Y1.06, P =0.13). Data on PFS were extracted from 3 publications, which reporting the 5-year PFS, 4-year PFS and 3-year PFS, respectively. There was no difference between weekly cisplatin and triweekly cisplatin regimens (odds ratio, 1.03; 95% CI, 0.78Y1.35, P =0.84). Figure 4 and Figure 5 showed the forest plot of OS and PFS. Risk of Publication Bias Publication bias was assessed using Begg s funnel plot, and no obvious asymmetry was presented. This suggests that there was no evidence of publication bias. DISCUSSION Previous studies demonstrated that locally advanced cancer had high recurrence rate after completion of radiation therapy in spite of improving the radiation equipment and techniques. 16 With the development of a series of large randomized trials (2Y6), the advantage of cisplatin-based concurrent chemoradiation was widely realized. Rose et al 5 found higher rates of survival and PFS among patients who were treated with radiotherapy and cisplatin-based chemotherapy. The reason is that cisplatin could enhance the effects of FIGURE 3. Forest plot of gastrointestinal toxicity. * 2016 IGCS and ESGO 347
5 Chen et al International Journal of Gynecological Cancer & Volume 27, Number 2, February 2017 FIGURE 4. Forest plot of the OS. radiation by restraining the repair of radiation-induced sublethal damage and sensitizing hypoxic cells to radiation. Although the most popular regimens are weekly cisplatin chemotherapy concurrent with radiotherapy, the optimal dose and regimen have not yet been defined. Thus, we performed this metaanalysis to evaluate the effectiveness of weekly and triweekly cisplatin concurrent chemoradiation, with 5 randomized controlled clinical trials included eventually. Nevertheless, the incidence of adverse reactions has been reported to be significantly higher in patients treated with concurrent chemoradiotherapy using cisplatin than that observed in the control group. 17 Hematologic toxicity is a severe problem in patients receiving concurrent chemoradiotherapy for treatment of cervical cancer, which often resulting in delayed or missed chemotherapy treatments and even impacting the prognosis. 18 The degree of hematologic toxicities, especially leucopenia, is one of the major dose-limiting factors in cisplatin administration. 17,19 Our analysis demonstrated that there was lower hematologic toxicity in weekly cisplatin 30 to 40 mg/m 2 than triweekly cisplatin 50 to 100 mg/m 2 chemotherapy concurrent with radiotherapy. This could be interpreted by the lower cisplatin dose and shorter duration of treatment. However for gastrointestinal complications, there was no discrepancy between the 2 chemoradiotherapy groups. Although the previous trials showed the superiority of compliance 8 and recurrence 9,15 in weekly cisplatin chemotherapy concurrent with radiotherapy, our study did not discover the obvious differentiation comparing weekly versus triweekly cisplatin arm. Weekly cisplatin regimen was considerable and feasible, though it was not superior in the OS and PFS than triweekly cisplatin. Kim et al 14 reported that weekly cisplatin group had the same treatment outcomes as the triweekly cisplatin group but with less toxicity. Furthermore, the arm of weekly cisplatin has the advantage of not requiring hospitalization. 8 Therefore, we recommend the weekly cisplatin 30 FIGURE 5. Forest plot of the PFS. 348 * 2016 IGCS and ESGO
6 International Journal of Gynecological Cancer & Volume 27, Number 2, February 2017 Weekly vs Triweekly Cisplatin Chemoradiotherapy to 40 mg/m 2 chemoradiotherapy as the strong candidate for the optimal cisplatin dose and dosing schedule in the treatment of locally advanced cervical cancer. REFERENCES 1. Garcia AA, Blessing JA, Darcy KM, et al. Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: a gynecologic oncology group study. Gynecol Oncol. 2007;104:572Y Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154Y Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340: 1137Y Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606Y Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144Y Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol. 1999;17:1339Y Lanciano R, Calkins A, Bundy BN, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. J Clin Oncol. 2005;23:8289Y Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer. Gynecol Oncol. 2008;108:195Y Nagy VM, Ordeanu C, Coza O, et al. Randomized phase 3 trial comparing 2 cisplatin dose schedules in 326 patients with locally advanced squamous cell cervical carcinoma: long-term follow-up. Int J Gynecol Cancer. 2012;22:1538Y Ryu SY, Lee WM, Kim K, et al. Randomized clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2011;81:e577Ye Hu Y, Cai ZQ, Su XY. Concurrent weekly cisplatin versus triweekly cisplatin with radiotherapy in the treatment of cervical cancer: a meta-analysis result. Asian Pac J Cancer Prev. 2012;13:4301Y das Nair R, Martin KJ, Lincoln NB. Memory rehabilitation for people with multiple sclerosis. Cochrane Database Syst Rev. 2016;3:CD Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557Y Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:2804Y DiSilvestro PA, Ali S, Craighead PS, et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study. J Clin Oncol. 2014;32:458Y Lanciano RM, Won M, Coia LR, et al. Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: a final report of the 1973 and 1978 patterns of care studies. Int J Radiat Oncol Biol Phys. 1991;20:667Y Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol. 2003;68:217Y Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001;358:781Y Ohno T, Kato S, Wakatsuki M, et al. Incidence and temporal pattern of anorexia, diarrhea, weight loss, and leukopenia in patients with cervical cancer treated with concurrent radiation therapy and weekly cisplatin: comparison with radiation therapy alone. Gynecol Oncol. 2006;103:94Y99. * 2016 IGCS and ESGO 349
Chapter 5 Stage III and IVa disease
Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include
More informationConcurrent chemoradiation in treatment of carcinoma cervix
N. J. Obstet. Gynaecol Vol. 2, No. 1, p. 4-8 May -June 2007 REVIEW Concurrent chemoradiation in treatment of carcinoma cervix Meeta Singh, Rajshree Jha, Josie Baral, Suniti Rawal Dept of Obs/Gyn, TU Teaching
More informationConcurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
Original Article J Gynecol Oncol Vol. 24, No. 2:108-113 http://dx.doi.org/10.3802/jgo.2013.24.2.108 pissn 2005-0380 eissn 2005-0399 Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk
More informationComparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail
Comparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail Dr. Nishee Srivastava MD, Dr. Kamal Sahani MD, Dr. Manoj
More informationRESEARCH ARTICLE. Ai-Qiu Qin 1&, Zhong-Guo Liang 2&, Jia-Xiang Ye 3 *, Jing Li 1, Jian-Li Wang 1, Chang-Xian Chen 1, Hong-Lin Song 1 * Abstract
10.14456/apjcp.2016.196/APJCP.2016.17..3945 RESEARCH ARTICLE Significant Efficacy of Additional Concurrent Chemotherapy with Radiotherapy for Postoperative Cervical Cancer with Risk Factors: a Systematic
More informationConcurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy in the Treatment of Locally Advanced Cervical Cancer
Med. J. Cairo Univ., Vol. 82, No. 2, March: 351-357, 2014 www.medicaljournalofcairouniversity.net Concurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy in the Treatment of Locally Advanced
More informationchemoradiation. Each of these trials had slightly different interventions,
Research ONCOLOGY Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial Frederick B. Stehman, MD; Shamshad Ali, MS, MStat;
More informationEui-Sok Sol 1, Tae Sung Lee 1, Suk Bong Koh 1, Hun Kyu Oh 2, Gi Won Ye 3, Youn Seok Choi 1 INTRODUCTION
J Gynecol Oncol Vol. 20, No. 1:28-34, March 2009 DOI:10.3802/jgo.2009.20.1.28 Original Article Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 5 MARCH 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical
More informationLong Term Outcome after Concurrent Chemo radiation with Cisplatin in Carcinoma Cervix
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i10.03 Long Term Outcome after Concurrent Chemo
More informationOutcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_
bs_bs_banner doi:10.1111/j.1447-0756.2012.01871.x J. Obstet. Gynaecol. Res. Vol. 38, No. 11: 1315 1320, November 2012 Outcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_1871
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationOriginal Date: June 2013 Page 1 of 7 Radiation Oncology Last Review Date: September Implementation Date: December 2014 Clinical Operations
National Imaging Associates, Inc. Clinical guideline CERVICAL CANCER Original Date: June 2013 Page 1 of 7 Radiation Oncology Last Review Date: September 2014 Guideline Number: NIA_CG_223 Last Revised Date:
More informationAuthor's response to reviews
Author's response to reviews Title:Randomized Phase III Trial of Radiotherapy or Chemoradiotherapy With Topotecan and Cisplatin in Intermediate-Risk Cervical Cancer Patients After Radical Hysterectomy
More informationLack of association between IL-6-174G>C polymorphism and lung cancer: a metaanalysis
Lack of association between IL-6-174G>C polymorphism and lung cancer: a metaanalysis Y. Liu, X.L. Song, G.L. Zhang, A.M. Peng, P.F. Fu, P. Li, M. Tan, X. Li, M. Li and C.H. Wang Department of Respiratory
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationThe Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy
The Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy Suisui Song, MD 1 ; Sonali Rudra, MD 1 ; Michael D. Hasselle, MD 2 ; Paige L. Dorn, MD 1 ; Loren
More informationORIGINAL ARTICLE. Summary. Introduction
Journal of BUON 17: 740-745, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Cisplatin monotherapy with concurrent radiotherapy versus combination of cisplatin and 5-fluorouracil
More informationAlectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis
Showa Univ J Med Sci 30 2, 309 315, June 2018 Original Alectinib Versus Crizotinib for Previously Untreated Alk-positive Advanced Non-small Cell Lung Cancer : A Meta-Analysis Ryo MANABE 1, Koichi ANDO
More informationPrognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases
Original Article J Gynecol Oncol Vol. 24, No. 3:229-235 pissn 2005-0380 eissn 2005-0399 Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic
More informationYukiharu Todo 1, Hidemichi Watari 2. Abstract
Review Article on Cervical Cancer Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups Yukiharu Todo
More informationOriginal article. Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy. to patients with carcinoma of the cervix uteri.
Annals of Oncology : 455^59, 2O00. 2000 Kluwer Academic Publishers. Printed in the Netherlands. Original article Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with
More informationQuimio Radioterapia en Cancer de Cervix
Quimio Radioterapia en Cancer de Cervix HIGINIA R. CÁRDENES PROFESSOR RADIATION ONCOLOGY CLINICAL DIRECTOR SCHNECK CANCER CENTER Worldwide incidence of cervical cancer 2014, 12.360 cases Global incidence
More informationRadiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
More informationEfficacy and Toxicity of Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Locally Advanced Cervical Cancer
original studies Efficacy and Toxicity of Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Locally Advanced Cervical Cancer Nemes Adina 1, Nagy Viorica 1, 2, Todor Nicolae 1, Marita Andreea 1,
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1999, by the Massachusetts Medical Society VOLUME 340 A PRIL 15, 1999 NUMBER 15 PELVIC RADIATION WITH CONCURRENT CHEMOTHERAPY COMPARED WITH PELVIC AND PARA-AORTIC
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationRadiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement
Original Article J Gynecol Oncol Vol. 23, No. 3:159-167 pissn 2005-0380 eissn 2005-0399 Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement
More informationComparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer
Original Article J Gynecol Oncol Vol. 23, No. 4:235-241 pissn 2005-0380 eissn 2005-0399 Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin
More informationINTRODUCTION. J. Radiat. Res., 53, (2012)
J. Radiat. Res., 53, 281 287 (2012) The Effects of Two HDR Brachytherapy Schedules in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiation: A Study from Chiang Mai, Thailand Ekkasit
More informationPrognostic significance of positive lymph node number in early cervical cancer
1052 Prognostic significance of positive lymph node number in early cervical cancer JUNG WOO PARK and JONG WOON BAE Department of Obstetrics and Gynecology, Dong A University Hospital, Dong A University
More informationNordic Society for Gynecological Oncology Advisory Board of Radiotherapy
Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy Guidelines for postoperative irradiation of cervical cancer Contents: 1. Treatment planning for EBRT. 2 2. Target definition for
More informationManagement of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.
Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
More informationCOMPARATIVE STUDY ON EFFICACY AND TOXICITY OF CHEMORADIOTHERAPY AND RADIOTHERAPY IN HEAD, NECK AND CERVIX CANCER PATIENTS
COMPARATIVE STUDY ON EFFICACY AND TOXICITY OF CHEMORADIOTHERAPY AND RADIOTHERAPY IN HEAD, NECK AND CERVIX CANCER PATIENTS E.Maheswari 1, G.R.Saraswathy 1, Santh Rani Thaakur 1, Narmada Sambhasivam 2. 1
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationIs Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2014;46(4):374-382 Original Article http://dx.doi.org/10.4143/crt.2013.084 Open Access Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationEditorial Process: Submission:09/12/2017 Acceptance:06/19/2018
DOI:10.22034/APJCP.2018.19.10.2745 Concurrent Chemo-Radiobrachytherapy in Cervical Cancer RESEARCH ARTICLE Editorial Process: Submission:09/12/2017 Acceptance:06/19/2018 Concurrent Chemo- Radiobrachytherapy
More informationOriginal Article INTRODUCTION. Abstract
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/251 A Prospective Analysis of Toxicities and Quality of Life after Treatment in Advanced Carcinoma Cervix Patients
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationPragyat Thakur 1,2, Rajeev Seam 1, Manoj Gupta 1, Manish Gupta 1. Introduction
Original Article on Newer Agents to Enhance Radiotherapeutic Outcomes Page 1 of 8 Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly
More informationThe clinicopathological features and treatment modalities associated with survival of neuroendocrine cervical carcinoma in a Chinese population
Zhang et al. BMC Cancer (2019) 19:22 https://doi.org/10.1186/s12885-018-5147-2 RESEARCH ARTICLE Open Access The clinicopathological features and treatment modalities associated with survival of neuroendocrine
More informationDATE: 22 May 2013 CONTEXT AND POLICY ISSUES
TITLE: Intraperitoneal versus Intravenous Chemotherapy for the Treatment of Ovarian Cancer: A Review of the Comparative Clinical Evidence, Safety, Cost- Effectiveness, and Guidelines DATE: 22 May 2013
More informationORIGINAL PAPER. Department of Radiology, Nagoya University Graduate School of Medicine, Aichi, Japan 2
Nagoya J. Med. Sci. 79. 211 ~ 220, 2017 doi:10.18999/nagjms.79.2.211 ORIGINAL PAPER Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine
More informationSmall cell lung cancer (SCLC) accounts for approximately
ORIGINAL ARTICLE A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer Jingwei
More informationONCOLOGY REPORTS 19: , 2008
ONCOLOGY REPORTS 19: 1551-1556, 2008 A phase II multicenter trial of concurrent chemoradiotherapy with weekly nedaplatin in advanced uterine cervical carcinoma: Tohoku Gynecologic Cancer Unit Study YOSHIHITO
More informationChun-Chieh Wang, MD and Feng-Yuan Liu, MD/ Prof. Chyong-Huey Lai, MD
Concept/trial design presentation A Phase 2 Trial of Pembrolizumab Combined with Chemoradiation for Patients with [ 18 F]-FDG PET/CT-defined Poor-prognostic Cervical Cancer Chun-Chieh Wang, MD and Feng-Yuan
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationINTRODUCTION PATIENT. J. Radiat. Res., 52, (2011)
J. Radiat. Res., 52, 54 58 (2011) Regular Paper Intracavitary Combined with CT-guided Interstitial Brachytherapy for Locally Advanced Uterine Cervical Cancer: Introduction of the Technique and a Case Presentation
More informationONCOLOGY LETTERS 3: , 2012
ONCOLOGY LETTERS 3: 641-645, 2012 Treatment of early bulky cervical cancer with neoadjuvant paclitaxel, carboplatin and cisplatin prior to laparoscopical radical hysterectomy and pelvic lymphadenectomy
More informationORIGINAL PAPER. Departments of Radiology, Nagoya University Graduate School of Medicine, Nagoya Japan 2
Nagoya J. Med. Sci. 76. 11 ~ 16, 2014 ORIGINAL PAPER RETROSPECTIVE CASE SERIES OF 15 PATIENTS TREATED WITH CHEMORADIATION USING 5-FU AND NEDAPLATIN FOR GYNECOLOGICAL MALIGNANCY: WITH REGARD TO HEMOTOXICITY
More informationProspective comparative study of dose dense neo-adjuvant chemotherapy followed by chemo-radiation and definitive chemoradiation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Karpurmath SV et al. Int J Reprod Contracept Obstet Gynecol. 2016 Sept;5(9):2909-2914 www.ijrcog.org pissn 2320-1770 eissn
More informationThree-Dimensional Conformal Radiotherapy for Stage IIB- IIIB Cervical Cancer: Experience of the Oncology Institute Prof.Dr. Ion Chiricuta Cluj-Napoca
original studies Three-Dimensional Conformal Radiotherapy for Stage IIB- IIIB Cervical Cancer: Experience of the Oncology Institute Prof.Dr. Ion Chiricuta Cluj-Napoca Anamaria Sipos 1, Noemi Besenyodi
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationCervical CA: What is Advanced Stage? If the tumor is early stage but >4cm (IB2 or IIA2), it is often treated as advanced stage (category 1) but also h
PROGRAMA 2 Taller Internacional Multidisciplinario de Cancer de Mama y Cuello Uterino Racional del tratamiento combinado con Quimioterapia e Irradiación. Resultados en Cáncer de Cérvix avanzado Higinia
More informationHypofractionated RT in Cervix Cancer. Anuja Jhingran, MD
Hypofractionated RT in Cervix Cancer Anuja Jhingran, MD Hypofractionated RT in Cervix Cancer: Clinicaltrials.gov 919 cervix trials 134 hypofractionated RT trials Prostate, breast, NSCLC, GBM 0 cervix trials
More informationECC or Margins Positive?
CLINICAL PRESENTATION This practice algorithm has been specifically developed for M. D. Anderson using a multidisciplinary approach and taking into consideration circumstances particular to M. D. Anderson,
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Prophylactic cranial irradiation in patients with non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled
More informationHigh-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible??
DOI 10.1007/s13224-015-0812-8 ORIGINAL ARTICLE High-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible?? Saptarshi Ghosh 1 Pamidimukalabramhananda
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More informationSurvival Benefits of Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy in Locally Advanced Chemoresistant Cervical Cancer
J Korean Med Sci 2006; 21: 683-9 ISSN 1011-8934 Copyright The Korean Academy of Medical Sciences Survival Benefits of Neoadjuvant Chemotherapy Followed by Radical Surgery versus Radiotherapy in Locally
More informationKe Hu, Weiping Wang, Xiaoliang Liu, Qingyu Meng and Fuquan Zhang *
Hu et al. Radiation Oncology (2018) 13:249 https://doi.org/10.1186/s13014-018-1197-5 RESEARCH Open Access Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after
More informationA meta-analysis of clinical trials over regimens with or without cetuximab for advanced gastric cancer patients
JBUON 2017; 22(4): 900-904 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE A meta-analysis of clinical trials over regimens with or without cetuximab
More informationOriginal Article. Introduction. Soyi Lim 1, Seok-Ho Lee 2, Kwang Beom Lee 1, Chan-Yong Park 1
Original Article Obstet Gynecol Sci 2016;59(3):184-191 http://dx.doi.org/10.5468/ogs.2016.59.3.184 pissn 2287-8572 eissn 2287-8580 The influence of number of high risk factors on clinical outcomes in patients
More informationChemotherapy for Cervical Cancer. Matsue City Hospital Junzo Kigawa
Chemotherapy for Cervical Cancer Matsue City Hospital Junzo Kigawa Introduction Worldwide, cervical cancer is the second most common cancer in women and affects 530,000 new patients and 275,000 deaths.
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationThe New England Journal of Medicine
CISPLATIN, RADIATION, AND ADJUVANT HYSTERECTOMY COMPARED WITH RADIATION AND ADJUVANT HYSTERECTOMY FOR BULKY STAGE IB CERVICAL CARCINOMA HENRY M. KEYS, M.D., BRIAN N. BUNDY, PH.D., FREDERICK B. STEHMAN,
More informationGemcitabine and cisplatin regimen facilitates prognosis of advanced nasopharyngeal carcinoma
Received: 9 January 2018 Revised: 27 April 2018 DOI: 10.1002/cam4.1575 Accepted: 1 May 2018 ORIGINAL RESEARCH Gemcitabine and cisplatin regimen facilitates prognosis of advanced nasopharyngeal carcinoma
More informationDe-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
More informationConcurrent chemoradiation in locally advanced carcinoma cervix patients
Original Article Free full text available from www.cancerjournal.net Concurrent chemoradiation in locally advanced carcinoma cervix patients ABSTRACT Purpose: To investigate the feasibility of concurrent
More informationACR Appropriateness Criteria Advanced Cervical Cancer EVIDENCE TABLE
. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet 009; 05():07-08.. Mitchell DG, Snyder B, Coakley F, et al. Early invasive cervical cancer:
More informationChemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is
More information9. The role of cytoreductive surgery in cervical cancer: Is there a benefit of retroperitoneal lymph node debulking in advanced disease?
Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach, 2010: 161-172 ISBN: 978-81-7895-484-4 Editor:
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationImpact of Radiotherapy with and without Concurrent Cisplatin on Lymphocyte Subpopulations in Cervical Cancer Patients
Impact of Radiotherapy with and without Concurrent Cisplatin on Lymphocyte Subpopulations in Cervical Cancer Patients BARBARA BACHTIARY 1, IRENE HERBACEK 2, THOMAS ZIDECK 2, THOMAS-HENDRIK KNOCKE 1, JOHANNES
More informationThe Efficacy and Safety of Neoadjuvant Chemotherapy in Treatment of Locally Advanced Carcinoma Cervix
The Journal of Obstetrics and Gynecology of India (July August 2013) 63(4):273 278 DOI 10.1007/s13224-012-0342-6 ORIGINAL ARTICLE The Efficacy and Safety of Neoadjuvant Chemotherapy in Treatment of Locally
More informationEffectiveness of cervical cancer therapy using neoadjuvant chemotherapy in combination with radical surgery: a metaanalysis
Original Article Effectiveness of cervical cancer therapy using neoadjuvant chemotherapy in combination with radical surgery: a metaanalysis Yijie Fu 1, Tianmin Zhu 2, Hui Li 3 1 Department of Internal
More informationCompleting or Abandoning Radical Hysterectomy in Early-Stage Lymph NodeYPositive Cervical Cancer
ORIGINAL STUDY Completing or Abandoning Radical Hysterectomy in Early-Stage Lymph NodeYPositive Cervical Cancer Impact on Disease-Free Survival and Treatment-Related Toxicity Marloes Derks, MD,* Freek
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationA meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer
Original Article A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer Weisan Zhang 1, Qian Liu 2, Xifeng Dong 3, Ping Lei 1 1 Department
More informationWenze Sun, Tao Wang, Fan Shi, Jiquan Wang, Juan Wang, Beina Hui, Yingbing Zhang, Jinli Lu, Hongwei Chen and Zi Liu *
Sun et al. BMC Cancer (2015) 15:353 DOI 10.1186/s12885-015-1355-1 RESEARCH ARTICLE Open Access Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk
More informationThe type of metastasis is a prognostic factor in disseminated cervical cancer
J Gynecol Oncol Vol. 21, No. 3:186-190, September 2010 DOI:10.3802/jgo.2010.21.3.186 Original Article The type of metastasis is a prognostic factor in disseminated cervical cancer Kidong Kim 1, Soo Youn
More informationIntra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical cancer
Arch Gynecol Obstet (2012) 285:811 816 DOI 10.1007/s00404-011-2038-z GYNECOLOGIC ONCOLOGY Intra-operative frozen section analysis of common iliac lymph nodes in patients with stage IB1 and IIA1 cervical
More informationAdjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals
6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy
More informationSelf-Assessment Module 2016 Annual Refresher Course
LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns
More informationManagement of Cervical Cancer in Resource Limited Settings
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD MPH MS Professor, Gynecologic Oncology Icahn School of Medicine at Mount Sinai New York NY 84% of incidence and death occur in
More informationConcomitant chemo-radiation in locally advanced carcinoma of the cervix
J Obstet Gynecol India Vol. 57, No. 2: March/April 2007 Pg 145-150 ORIGINAL ARTICLE The Journal of Obstetrics and Gynecology of India Concomitant chemo-radiation in locally advanced carcinoma of the cervix
More informationMETHODS. Study population. Treatment schedule
British Journal of Cancer (2007) 97, 1058 1062 All rights reserved 0007 0920/07 $30.00 www.bjcancer.com Treatment of squamous cell carcinoma of the uterine cervix with radiation therapy alone: long-term
More informationARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews High-dose chemotherapy followed by autologous haematopoietic cell transplantation for children, adolescents and young adults with first
More informationAnalysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix
DOI 10.1007/s11805-009-0133-8 133 Analysis of rognosis and rognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix Guangwen Yuan Lingying Wu Xiaoguang Li Manni Huang Department
More informationThe relationship between positive peritoneal cytology and the prognosis of patients with FIGO stage I/II uterine cervical cancer
Original Article J Gynecol Oncol Vol. 25,. 2:9-96 http://dx.doi.org/.382/jgo.24.25.2.9 pissn 25-38 eissn 25-399 The relationship between positive peritoneal cytology and the prognosis of patients with
More informationBiomedical Research 2018; 29 (10):
Biomedical Research 2018; 29 (10): 2116-2121 ISSN 0970-938X www.biomedres.info Concurrent chemoradiotherapy with paclitaxel and cisplatin for patients of locally advanced cervical squamous cell carcinoma:
More informationCancerous esophageal stenosis before treatment was significantly correlated to poor prognosis of patients with esophageal cancer: a meta-analysis
Original Article Cancerous before treatment was significantly correlated to poor prognosis of patients with cancer: a meta-analysis Han-Yu Deng 1,2#, Guha Alai 1#, Jun Luo 1#, Gang Li 1, Ze-Guo Zhuo 1,
More information